Sue Robinson

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 816 citations

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 319 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +14

Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial

Marc Rodger, William M. Hague, John‏ Kingdom et al. · The Lancet · 2014 · 244 citations

Thrombosis, Maternal Complication, Reproductive Health +10

A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7

Chaim Shustik, Andrew R. Belch, Sue Robinson et al. · British Journal of Haematology · 2006 · 82 citations · Full text

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

John C. Byrd, Amy S. Ruppert, Nyla A. Heerema et al. · Blood Advances · 2018 · 22 citations · Full text